EVI27 Inhibitors
Chemical inhibitors of EVI27 can selectively impede various signaling pathways and cellular processes that are crucial for the protein's function. Wortmannin and LY294002 are two such inhibitors that target phosphoinositide 3-kinases (PI3K), which are instrumental in endosomal trafficking. By inhibiting PI3K, these chemicals can disrupt the endocytic pathway, leading to a blockade of EVI27's activity in these processes. Similarly, U0126 acts upon the MEK component of the MAPK/ERK pathway, a pathway known to regulate endocytosis and endosomal dynamics, which are processes potentially governed by EVI27. Another MAPK pathway inhibitor, SB203580, targets p38 MAP kinase, which if involved in EVI27-mediated responses, would be impaired, leading to a reduction in EVI27's ability to facilitate cellular reactions to stress and inflammation.
Further inhibitors such as SP600125, which targets c-Jun N-terminal kinase (JNK) within the MAPK pathways, can alter the cellular context by modifying apoptosis and inflammatory responses, thereby affecting EVI27's role in these processes. Genistein, a broad-spectrum tyrosine kinase inhibitor, can interrupt phosphorylation events that may be required for EVI27's regulation or activity. Src family tyrosine kinases, which are involved in cell growth and differentiation, can be inhibited by PP2, possibly leading to a reduction in EVI27's regulatory functions. PD98059, another MEK inhibitor, disrupts the MAPK/ERK pathway similar to U0126, impacting EVI27 activity associated with this pathway. Small GTPase inhibitors such as NSC23766 and ML141 target Rac1 and Cdc42, respectively, and by doing so, they can impede the reorganization of the actin cytoskeleton necessary for EVI27's endocytic function. Go6983, a pan-protein kinase C (PKC) inhibitor, could impair EVI27 by halting processes regulated by PKC, such as vesicle formation and trafficking. Lastly, Bafilomycin A1, by inhibiting the V-ATPase proton pump, can affect the acidification of endosomes and lysosomes, a critical step for many endosomal-lysosomal pathway functions in which EVI27 might be involved.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in signaling pathways that regulate various cellular processes including metabolism, growth, and survival. Inhibition of PI3K by Wortmannin could lead to the functional inhibition of EVI27 by preventing the PI3K-dependent endosomal trafficking required for EVI27's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 would disrupt the PI3K signaling pathway, thereby potentially inhibiting the endosomal trafficking processes that EVI27 is involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. Since the MAPK/ERK pathway can regulate endocytosis and endosomal dynamics, inhibition by U0126 could potentially impair the function of EVI27 related to these processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, another enzyme in the MAPK signaling pathway. Inhibition of p38 MAPK can disrupt cellular responses to stress and inflammation, which might be necessary for the proper functioning of EVI27, particularly if EVI27 is involved in stress-induced endocytosis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), part of the MAPK signaling pathways. Inhibition of JNK can alter cellular processes such as apoptosis and inflammation, potentially disrupting the cellular context in which EVI27 operates, particularly if EVI27 function is related to these processes. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can disrupt various signaling pathways by inhibiting phosphorylation events. If EVI27 requires phosphorylation for its function or is regulated by kinases that genistein inhibits, this compound could result in the functional inhibition of EVI27. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases are involved in regulating various cellular processes including cell growth and differentiation. If EVI27 is regulated by Src kinases, PP2 could inhibit its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can disrupt the MAPK/ERK pathway and could inhibit the function of EVI27 if it is involved in MAPK/ERK pathway-regulated processes. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a potent and selective inhibitor of Cdc42, another GTPase involved in the regulation of the actin cytoskeleton. If EVI27 function is linked to actin dynamics or Cdc42-regulated pathways, ML141 could inhibit the function of EVI27. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a pan-protein kinase C (PKC) inhibitor. PKC is involved in a wide range of cellular functions, including vesicle formation and trafficking. If EVI27 is part of a pathway regulated by PKC, inhibition by Go6983 could impair EVI27 function. | ||||||